The investigation and treatment of hypertension, a leading risk factor for cardiovascular disease throughout the world, remains a challenge, even in developed countries. Although antihypertensives have been available for 50 years, the rational and effective use of the myriad of existing drugs remains a concern, as does the desire to identify patients with secondary hypertension from the mass of individuals with primary or essential hypertension. The...